Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
RMD

RMD - ResMed Inc Stock Price, Fair Value and News

218.56USD-1.41 (-0.64%)Delayed

Market Summary

RMD
USD218.56-1.41
Delayed
-0.64%

RMD Alerts

  • 1 major insider sales recently.

RMD Stock Price

View Fullscreen

RMD RSI Chart

RMD Valuation

Market Cap

32.1B

Price/Earnings (Trailing)

33.5

Price/Sales (Trailing)

7

EV/EBITDA

25.11

Price/Free Cashflow

29.47

RMD Price/Sales (Trailing)

RMD Profitability

EBT Margin

25.83%

Return on Equity

20.7%

Return on Assets

14.06%

Free Cashflow Yield

3.39%

RMD Fundamentals

RMD Revenue

Revenue (TTM)

4.6B

Rev. Growth (Yr)

7.17%

Rev. Growth (Qtr)

2.94%

RMD Earnings

Earnings (TTM)

958.4M

Earnings Growth (Yr)

29.24%

Earnings Growth (Qtr)

43.91%

Breaking Down RMD Revenue

Last 7 days

2.2%

Last 30 days

25.7%

Last 90 days

21.1%

Trailing 12 Months

-2.3%

How does RMD drawdown profile look like?

RMD Financial Health

Current Ratio

3.04

Debt/Equity

0.22

Debt/Cashflow

1.2

RMD Investor Care

Dividend Yield

0.86%

Dividend/Share (TTM)

1.88

Buy Backs (1Y)

0.02%

Diluted EPS (TTM)

6.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.6B000
20234.0B4.2B4.4B4.5B
20223.5B3.6B3.6B3.8B
20213.1B3.2B3.3B3.4B
20202.9B3.0B3.0B3.1B
20192.5B2.6B2.7B2.8B
20182.3B2.3B2.4B2.5B
20172.0B2.1B2.1B2.2B
20161.8B1.8B1.9B2.0B
20151.6B1.7B1.7B1.7B
20141.6B1.6B1.6B1.6B
20131.5B1.5B1.5B1.5B
20121.3B1.4B1.4B1.4B
20111.2B1.2B1.3B1.3B
20101.0B1.1B1.1B1.2B
20090920.7M963.6M1.0B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of ResMed Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 07, 2024
farrell michael j.
sold
-3,178,820
216
-14,683
chief executive officer
May 07, 2024
farrell michael j.
acquired
1,247,760
84.98
14,683
chief executive officer
Apr 29, 2024
burt carol
gifted
-
-
-234
-
Apr 29, 2024
drexler karen
sold
-91,341
214
-425
-
Mar 04, 2024
rider michael j
sold
-14,580
180
-81.00
global general counsel
Mar 01, 2024
rider michael j
sold
-34,650
173
-200
global general counsel
Feb 22, 2024
farrell peter c
sold
-1,997,430
182
-10,935
-
Nov 27, 2023
sandercock brett
sold
-457,860
152
-3,000
chief financial officer
Nov 22, 2023
rider michael j
gifted
-
-
-72.00
global general counsel
Nov 20, 2023
farrell michael j.
sold (taxes)
-350,445
148
-2,352
chief executive officer

1–10 of 50

Which funds bought or sold RMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
SkyView Investment Advisors, LLC
new
-
503,000
503,000
0.09%
May 16, 2024
Motley Fool Asset Management LLC
added
12.58
223,877
980,249
0.06%
May 16, 2024
Beacon Capital Management, LLC
unchanged
-
3,010
11,882
-%
May 16, 2024
2Xideas AG
reduced
-30.14
-10,408,800
42,750,700
5.23%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-84.11
-74,478,900
16,671,600
-%
May 16, 2024
Global Financial Private Client, LLC
unchanged
-
87.00
947
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
0.51
6,252,480
46,050,700
0.06%
May 16, 2024
Tidal Investments LLC
added
58.2
799,528
1,773,160
0.03%
May 16, 2024
Pineridge Advisors LLC
reduced
-6.00
18,355
241,849
0.09%
May 16, 2024
COMERICA BANK
reduced
-3.11
597,181
5,771,530
0.03%

1–10 of 38

Are Funds Buying or Selling RMD?

Are funds buying RMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RMD
No. of Funds

Unveiling ResMed Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
12.56%
18,478,846
SC 13G/A
Jan 25, 2024
blackrock inc.
8.7%
12,783,715
SC 13G/A
Feb 10, 2023
wcm investment management, llc
2.6%
3,832,642
SC 13G/A
Feb 09, 2023
vanguard group inc
11.63%
17,028,881
SC 13G/A
Feb 07, 2023
blackrock inc.
9.4%
13,774,787
SC 13G/A
Feb 10, 2022
vanguard group inc
11.06%
16,119,963
SC 13G/A
Feb 10, 2022
wcm investment management, llc
6.21%
9,046,150
SC 13G/A
Feb 01, 2022
blackrock inc.
9.3%
13,561,224
SC 13G/A
Feb 10, 2021
wcm investment management, llc
6.09%
8,821,570
SC 13G/A
Feb 10, 2021
vanguard group inc
10.65%
15,439,844
SC 13G/A

Recent SEC filings of ResMed Inc

View All Filings
Date Filed Form Type Document
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 15, 2024
144
Notice of Insider Sale Intent
May 10, 2024
4
Insider Trading
May 09, 2024
4
Insider Trading
May 08, 2024
144
Notice of Insider Sale Intent
May 07, 2024
144
Notice of Insider Sale Intent
Apr 30, 2024
4
Insider Trading
Apr 30, 2024
4
Insider Trading
Apr 29, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to ResMed Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.0B
40.3B
-1.75% -4.07%
32.18
4.49
-2.84% -3.08%
68.3B
19.7B
1.78% -6.05%
51.24
3.46
4.82% -17.56%
20.4B
3.9B
-9.57% -7.50%
44.2
5.22
5.72% 46.72%
18.0B
14.9B
-10.73% -18.01%
6.79
1.21
2.98% 207.68%
MID-CAP
9.8B
3.5B
6.68% 24.08%
31.27
2.76
6.16% 35.06%
9.6B
12.5B
6.31% -2.51%
24.63
0.77
-0.61% -18.83%
8.4B
2.6B
1.13% -22.65%
-26.02
3.22
-6.25% -68.62%
5.9B
3.9B
-6.79% -30.12%
-62.84
1.49
0.23% 91.03%
3.4B
387.1M
0.52% 31.17%
-216.3
8.9
30.82% 65.57%
2.3B
6.6B
0.19% -5.50%
11.93
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
5.94% -10.00%
-1.91
0.41
7.94% -1661.78%
376.6M
169.3M
-1.13% -2.23%
-4.9
2.23
7.49% -244.90%
241.9M
324.0M
-4.58% -37.15%
-1.26
0.75
-3.19% -337.41%
56.1M
50.5M
22.73% -73.49%
-2.46
1.11
14.25% -10.06%
1.0M
3.7M
-71.13% 32.26%
-0.09
0.28
5.77% 8.23%

ResMed Inc News

Latest updates
MarketBeat21 hours ago
Yahoo Canada Finance47 hours ago
Yahoo Finance15 May 202404:45 pm
Yahoo Finance15 May 202401:45 pm
MarketWatch14 May 202409:02 pm
MarketWatch15 Apr 202407:00 am

ResMed Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue2.9%1,1971,1631,1021,1221,1171,034950915865895904876769800752770769736681705662
Gross Profit7.1%693647600617618580541523491504506491447462439449450427392399381
Operating Expenses-14.4%318372311342317300265267257256244249224241222226232229221278224
  S&GA Expenses3.5%230222223240228212194193182185177181160169159165172171167172165
  R&D Expenses4.3%77.0074.0076.0078.0076.0070.0063.0064.0067.0063.0060.0060.0056.0055.0055.0053.0051.0050.0048.0051.0048.00
EBITDA Margin5.4%0.29*0.27*0.28*0.29*0.29*0.30*0.30*0.31*0.30*0.31*0.31*0.32*---------
Interest Expenses20.1%-11.03-13.80-14.96-14.94-14.96-10.34-7.13-5.54-5.46-5.95-5.36-41.976.006.007.00-70.5410.0010.0011.0013.0012.00
Income Taxes47.9%75.0051.0053.0047.0057.0049.0051.0043.0047.0036.0055.0044.0029631.0037.0034.0029.0018.0030.0027.0033.00
Earnings Before Taxes44.7%37525927227728927426223822623725923921821121621219217915196.00138
EBT Margin6.0%0.26*0.24*0.25*0.26*0.26*0.27*0.27*0.27*0.27*0.28*0.28*0.28*---------
Net Income43.9%300209219230233225210195179202204195-78.4818017817816316112069.00105
Net Income Margin5.8%0.21*0.20*0.21*0.21*0.21*0.22*0.22*0.22*0.22*0.15*0.15*0.15*---------
Free Cashflow52.7%38124925620325410116.0051.0069.00189-93.00199---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.3%6,8156,9056,7416,7526,7146,6765,1785,0964,9054,7354,7294,7284,5864,5734,6214,5874,5114,3544,1554,1084,099
  Current Assets-1.1%2,3512,3782,3052,3682,3382,3252,0341,9311,7041,5471,5861,5751,4661,4511,5431,5231,4701,3001,1611,1451,103
    Cash Equivalents13.2%238210209228228253207274202194276295231256421463353204172147147
  Inventory-11.1%8299339589981,011989865744665592507457484475478417359378357350320
  Net PPE-2.2%540552534538529523487498513478467463455459425417397408383387382
  Goodwill-0.9%2,8362,8622,8122,7702,7842,7671,9391,9361,9461,9511,9221,9281,9261,9101,9001,8901,8841,8711,8561,8561,939
Liabilities-9.8%2,1852,4232,4902,6222,7812,9381,7451,7351,6261,5891,7031,8421,8761,7081,9422,0902,2542,0962,0372,0352,077
  Current Liabilities1.2%773764771759762733693689667621624912877577591603552500550556463
  Short Term Borrowings0.1%10.0010.0010.0010.0010.0010.0010.0010.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.00
  Long Term Debt-18.1%9971,2171,3521,4311,5761,7917857656696687946437198141,0441,1641,3651,2881,2081,2591,323
Shareholder's Equity3.3%4,6304,4824,2504,1303,9333,7383,4333,3613,2793,1463,0262,8862,7092,8652,6792,4972,2562,2582,1172,0722,021
  Retained Earnings5.1%4,7704,5404,4024,2534,0883,9203,7603,6143,4803,3633,2223,0802,9413,0772,9542,8332,7122,6052,5012,4362,421
  Additional Paid-In Capital1.4%1,8481,8231,7911,7721,7291,7111,7021,6821,6451,6291,6441,6221,5871,5741,5881,5711,5341,5221,5301,5111,476
Shares Outstanding-0.1%147147147147147147146146146146146145---------
Float------30,201---37,771---30,662---22,240---
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations47.4%40227328623728312945.0079.00117220-65.6622719617014433024070.00162142140
  Share Based Compensation3.0%20.0020.0019.0020.0018.0016.0017.0016.0016.0016.0017.0017.0016.0015.0016.0016.0014.0014.0013.0014.0013.00
Cashflow From Investing19.4%-33.15-41.14-148-46.52-28.10-1,026-58.81-55.24-49.49-83.31-41.87-48.07-58.62-29.66-22.11-3.41-99.61-43.62-33.22-43.89-225
Cashflow From Financing-40.6%-335-238-151-188-279933-41.8857.00-60.86-21793.00-114-158-316-175-23618.001.00-100-97.5783.00
  Dividend Payments-0.3%70.0071.0071.0065.0065.0065.0064.0061.0061.0061.0061.0057.0057.0057.0057.0056.0056.0056.0056.0053.0053.00
  Buy Backs-50.00--------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RMD Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Net revenue$ 1,196,980$ 1,116,898$ 3,462,102$ 3,100,936
Cost of sales (exclusive of amortization shown separately below)496,387490,8241,497,3501,340,660
Amortization of acquired intangible assets7,8128,32224,97622,001
Total cost of sales504,199499,1461,522,3261,362,661
Gross profit692,781617,7521,939,7761,738,275
Operating Expenses    
Selling, general, and administrative229,919228,457674,948633,317
Research and development77,07476,436226,664209,498
Amortization of acquired intangible assets11,20412,18835,25929,701
Restructuring expenses (note 11)0064,2280
Acquisition related expenses0009,157
Total operating expenses318,197317,0811,001,099881,673
Income from operations374,584300,671938,677856,602
Other income (loss), net:    
Interest (expense) income, net(11,026)(14,964)(39,787)(32,436)
Gain (loss) attributable to equity method investments (note 5)440(183)(2,716)(5,037)
Gain on equity investments (note 5)13,9196,41811,42911,506
Other, net(2,496)(2,564)(537)(5,773)
Total other income (loss), net837(11,293)(31,611)(31,740)
Income before income taxes375,421289,378907,066824,862
Income taxes74,92956,878178,351156,970
Net income$ 300,492$ 232,500$ 728,715$ 667,892
Basic earnings per share (in dollars per share)$ 2.04$ 1.58$ 4.96$ 4.55
Diluted earnings per share (in dollars per share)2.041.584.944.53
Dividend declared per share (in dollars per share)$ 0.48$ 0.44$ 1.44$ 1.32
Basic shares outstanding (000's) (in shares)146,959146,914147,056146,681
Diluted shares outstanding (000's) (in shares)147,450147,395147,549147,400
Total Sleep and Respiratory Care    
Net revenue$ 1,049,023$ 980,116$ 3,029,915$ 2,741,541
Cost of sales (exclusive of amortization shown separately below)448,434443,9251,353,6151,214,072
Amortization of acquired intangible assets1,0541,3674,2943,939
Software as a Service    
Net revenue147,957136,782432,187359,395
Cost of sales (exclusive of amortization shown separately below)47,95346,899143,735126,588
Amortization of acquired intangible assets$ 6,758$ 6,955$ 20,682$ 18,062

RMD Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Jun. 30, 2023
Current assets:  
Cash and cash equivalents$ 237,910$ 227,891
Accounts receivable, net of allowances of $19,810 and $23,603 at March 31, 2024 and June 30, 2023, respectively779,265704,909
Inventories (note 3)829,458998,012
Prepaid expenses and other current assets (note 3)504,663437,018
Total current assets2,351,2962,367,830
Non-current assets:  
Property, plant and equipment, net (note 3)539,743537,856
Operating lease right-of-use assets147,075127,955
Goodwill (note 4)2,835,9932,770,299
Other intangible assets, net (note 3)501,024552,341
Deferred income taxes162,106132,974
Prepaid taxes and other non-current assets277,325262,453
Total non-current assets4,463,2664,383,878
Total assets6,814,5626,751,708
Current liabilities:  
Accounts payable177,445150,756
Accrued expenses356,076365,660
Operating lease liabilities, current24,18221,919
Deferred revenue150,753138,072
Income taxes payable54,67172,224
Short-term debt, net (note 7)9,9039,902
Total current liabilities773,030758,533
Non-current liabilities:  
Deferred revenue131,981119,186
Deferred income taxes86,56490,650
Operating lease liabilities, non-current136,313116,853
Other long-term liabilities47,55068,166
Long-term debt, net (note 7)997,0471,431,234
Long-term income taxes payable12,15737,183
Total non-current liabilities1,411,6121,863,272
Total liabilities2,184,6422,621,805
Commitments and contingencies (note 9)
Stockholders’ equity:  
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued00
Common stock, $0.004 par value, 350,000,000 shares authorized; 189,319,079 issued and 146,886,657 outstanding at March 31, 2024 and 188,900,583 issued and 147,064,349 outstanding at June 30, 2023588588
Additional paid-in capital1,847,9381,772,083
Retained earnings4,769,9634,253,016
Treasury stock, at cost, 42,432,422 shares at March 31, 2024 and 41,836,234 shares at June 30, 2023(1,723,263)(1,623,256)
Accumulated other comprehensive loss(265,306)(272,528)
Total stockholders’ equity4,629,9204,129,903
Total liabilities and stockholders’ equity$ 6,814,562$ 6,751,708
RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
 CEO
 WEBSITEresmed.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES10140

ResMed Inc Frequently Asked Questions


What is the ticker symbol for ResMed Inc? What does RMD stand for in stocks?

RMD is the stock ticker symbol of ResMed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ResMed Inc (RMD)?

As of Fri May 17 2024, market cap of ResMed Inc is 32.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RMD stock?

You can check RMD's fair value in chart for subscribers.

What is the fair value of RMD stock?

You can check RMD's fair value in chart for subscribers. The fair value of ResMed Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ResMed Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ResMed Inc a good stock to buy?

The fair value guage provides a quick view whether RMD is over valued or under valued. Whether ResMed Inc is cheap or expensive depends on the assumptions which impact ResMed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RMD.

What is ResMed Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RMD's PE ratio (Price to Earnings) is 33.5 and Price to Sales (PS) ratio is 7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ResMed Inc's stock?

In the past 10 years, ResMed Inc has provided 0.174 (multiply by 100 for percentage) rate of return.